IMMUNOSUPPRESSIVE DRUGS USED IN KIDNEY TRANSPLANTATION
Complications After Kidney Transplantation, Akademisyen Kitabevi, ss.1-15, 2026
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2026
- Doi Numarası: 10.37609/akya.4215.c12410
- Yayınevi: Akademisyen Kitabevi
- Sayfa Sayıları: ss.1-15
- Anahtar Kelimeler: immunosuppression, induction therapy, kidney transplantation, maintenance therapy, therapeutic drug monitoring
- Çukurova Üniversitesi Adresli: Evet
Özet
Kidney transplantation is the preferred treatment for end-stage kidney disease, and its success relies on the effective use of immunosuppressive therapy. This review summarizes current approaches to induction and maintenance immunosuppression, with a focus on risk-based treatment strategies. Induction therapy includes lymphocyte-depleting agents such as antithymocyte globulin and alemtuzumab, as well as non-depleting agents like basiliximab, selected according to immunological risk. Maintenance regimens are primarily based on calcineurin inhibitors, antiproliferative agents, and corticosteroids. Key determinants of therapy selection include human leukocyte antigen mismatch, panel reactive antibody levels, and donor-specific antibodies. Therapeutic drug monitoring is essential for optimizing immunosuppressive efficacy and minimizing toxicity. While potent agents improve rejection prevention in high-risk patients, they are associated with increased risks of infection and malignancy. In summary, modern immunosuppressive management in kidney transplantation is based on individualized risk assessment and careful balancing of efficacy and safety to achieve optimal graft and patient outcomes.